公开(公告)号：EP2142184B1

公开(公告)日：2018-10-24

申请号：EP08749978.6

申请日：2008-05-01

申请人： Novartis AG

发明人： BARDE, Yves-Alain ,  BILBE, Graeme ,  DEOGRACIAS, Ruben ,  KUHN, Rainer, R. ,  MATSUMOTO, Tomoya ,  MIR, Anis, Khusro ,  SCHUBART, Anna, Svenja

IPC分类号： A61K31/397 ,  A61K31/137 ,  A61K45/06 ,  A61P3/10 ,  A61P3/04 ,  A61P25/28 ,  A61P25/24 ,  A61P43/00

CPC分类号： A61K31/397 ,  A61K31/137 ,  A61K31/138 ,  A61K31/145 ,  A61K45/06

摘要： Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression.

公开(公告)号：EP2142184A1

公开(公告)日：2010-01-13

申请号：EP08749978.6

申请日：2008-05-01

申请人： Novartis AG

发明人： BARDE, Yves-Alain ,  BILBE, Graeme ,  DEOGRACIAS, Ruben ,  KUHN, Rainer, R. ,  MATSUMOTO, Tomoya ,  MIR, Anis, Khusro ,  SCHUBART, Anna, Svenja

IPC分类号： A61K31/137 ,  A61P3/10 ,  A61P3/04 ,  A61P25/28 ,  A61P25/24 ,  A61P43/00

CPC分类号： A61K31/397 ,  A61K31/137 ,  A61K31/138 ,  A61K31/145 ,  A61K45/06

摘要： Use of an S1P receptor modulator in the treatment or prevention of a disease or condition dependent on brain-derived neurotrophic factor (BDNF) expression.

公开(公告)号：EP1682103A1

公开(公告)日：2006-07-26

申请号：EP04790865.2

申请日：2004-10-26

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： AUBERSON, Yves ,  BILBE, Graeme ,  KUHN, Rainer, R. ,  VON MATT, Peter ,  RUEEGER, Heinrich ,  STAUFENBIEL, Matthias ,  WAGNER, Jürgen ,  ZIMMERMANN, Kaspar

IPC分类号： A61K31/00 ,  A61K31/496 ,  A61K31/517 ,  A61P25/00 ,  A61P25/28

CPC分类号： A61K31/00 ,  A61K31/496 ,  A61K31/517

摘要： The invention relates to the use of an inhibitor of formula (I), or a pharmaceutically acceptable salt thereof having an activity on protein kinases PKC alpha, PKC beta, PKC gamma, PKC epsilon, PKC theta, CDK-1, KDR, PKA, Flt-1, Flt-2, Flt-3 or Flt-4, or on a combination of the above enzymes, for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation such as neurodegenerative diseases like Down's Syndrome, memory and cognitive impairment, dementia, amyloid neuropathies, brain inflammation, nerve and brain trauma, vascular amyloidosis, or cerebral hemorrhage with amyloidosis.